Dr. Para studies laryngeal cancer, specifically the squamous cell carcinoma type. He examines how diagnosis, treatment strategies, and survival outcomes differ based on tumor location within the larynx. Additionally, he explores migraine treatments, particularly the use of anti-CGRP medications, and potential effects on bone health in patients. His research also investigates how individual factors like genetics and hypertension influence the effectiveness of migraine treatments.
Key findings
Survival rates for laryngeal cancer vary significantly based on tumor location, with various treatment approaches like surgery and radiation improving outcomes.
In a study of 51 migraine patients receiving anti-CGRP treatments, 53% were found to have osteopenia or osteoporosis, suggesting a risk for lower bone density.
52.7% of 110 patients treated with erenumab showed significant improvement in their migraine impact within three months, but high blood pressure was associated with a lower chance of improvement.
Frequently asked questions
Does Dr. Para study laryngeal cancer?
Yes, he investigates laryngeal cancer, focusing on diagnosis, treatment options, and survival outcomes.
What treatments has Dr. Para researched for migraines?
He has researched anti-CGRP medications and their effects on migraine patients, looking at both efficacy and potential risks.
Is Dr. Para's work relevant to patients with bone health concerns?
Yes, his findings on migraine treatments and bone density risks help both migraine patients and healthcare providers understand potential complications.
How does genetics affect migraine treatment outcomes?
Dr. Para's research indicates that certain genetic markers can increase the likelihood of improvement with migraine treatments like erenumab.
What are the risk factors associated with laryngeal cancer?
Key risk factors include smoking, alcohol use, and HPV infection, which can influence the progression and treatment of laryngeal cancer.
Publications in plain English
Laryngeal Cancer in the Modern Era: Evolving Trends in Diagnosis, Treatment, and Survival Outcomes.
2025
Journal of clinical medicine
Hut AR, Boia ER, Para D, Iovanescu G, Horhat D +5 more
Plain English This research paper looks at laryngeal cancer, particularly a type called squamous cell carcinoma, and how its diagnosis, treatment, and survival rates have changed over time. It finds that survival rates can vary significantly depending on where the tumor is located in the larynx (top, middle, or bottom) and highlights key risk factors like smoking, alcohol use, and HPV infection. The study underscores that many different approaches, including surgery and radiation, are necessary for the best treatment results.
Who this helps: This benefits patients dealing with laryngeal cancer and their healthcare providers.
Assessment of Bone Mineral Density Over 1 Year in a Cross-Sectional Cohort of Migraine Patients Receiving Anti-CGRP Monoclonal Antibodies.
2024
CNS drugs
Para D, Camponovo C, Riccitelli GC, Mallucci G, Maino P +5 more
Plain English This study looked at the bone density of migraine patients treated with anti-CGRP medications to see if these treatments increased the risk of bone problems. Of the 51 patients assessed, 27 (53%) had osteopenia or osteoporosis, indicating lower bone density. The study found that menopause and the use of anti-seizure drugs were linked to these bone issues, but there was no clear connection between the length of anti-CGRP treatment and bone density problems.
Who this helps: This helps migraine patients and their doctors understand potential risks related to bone health while using anti-CGRP treatments.
Response to erenumab assessed by Headache Impact Test-6 is modulated by genetic factors and arterial hypertension: An explorative cohort study.
2023
European journal of neurology
Zecca C, Terrazzino S, Para D, Campagna G, Viana M +2 more
Plain English This study looked at how genetic factors and high blood pressure affect the response to erenumab, a migraine treatment, in patients. Out of 110 patients treated, 59 (52.7%) showed significant improvement in their migraine impact within three months. It was found that having high blood pressure lowered the chances of improvement, while certain genetic markers increased those chances.
Who this helps: This benefits migraine patients and doctors by identifying who might respond better to treatment based on their genetics and health conditions.
Claudio Gobbi Chiara Zecca Alexandru-Romulus Hut Eugen Radu Boia Gheorghe Iovanescu Delia Horhat Loredan Mikša Maria Chiriac Raphaël Galant Alexandru Catalin Motofelea
Physician data sourced from the
NPPES NPI Registry
.
Publication data from
PubMed
.
Plain-English summaries generated by AI.
Not medical advice.